297 related articles for article (PubMed ID: 23639510)
1. In vivo magnetic resonance imaging of mice liver tumors using a new gadolinium-based contrast agent.
Chen SH; Kuo YT; Cheng TL; Chen CY; Chiu YY; Lai JJ; Chang CC; Jaw TS; Wang YM; Liu GC
Kaohsiung J Med Sci; 2013 May; 29(5):246-53. PubMed ID: 23639510
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
[TBL] [Abstract][Full Text] [Related]
3. A new biodegradable and biocompatible gadolinium (III) -polymer for liver magnetic resonance imaging contrast agent.
Xiao Y; Xue R; You T; Li X; Pei F
Magn Reson Imaging; 2015 Jul; 33(6):822-8. PubMed ID: 25839395
[TBL] [Abstract][Full Text] [Related]
4. Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A.
Erstad DJ; Ramsay IA; Jordan VC; Sojoodi M; Fuchs BC; Tanabe KK; Caravan P; Gale EM
Invest Radiol; 2019 Nov; 54(11):697-703. PubMed ID: 31356382
[TBL] [Abstract][Full Text] [Related]
5. Development of a Gd(III)-based receptor-induced magnetization enhancement (RIME) contrast agent for β-glucuronidase activity profiling.
Chen SH; Kuo YT; Singh G; Cheng TL; Su YZ; Wang TP; Chiu YY; Lai JJ; Chang CC; Jaw TS; Tzou SC; Liu GC; Wang YM
Inorg Chem; 2012 Nov; 51(22):12426-35. PubMed ID: 23116118
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a Gadolinium-Based Nanoparticle (AGuIX) for Contrast-Enhanced MRI of the Liver in a Rat Model of Hepatic Colorectal Cancer Metastases at 9.4 Tesla.
Fries P; Morr D; Müller A; Lux F; Tillement O; Massmann A; Seidel R; Schäfer T; Menger MD; Schneider G; Bücker A
Rofo; 2015 Dec; 187(12):1108-15. PubMed ID: 26361379
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging.
Chong HS; Garmestani K; Bryant LH; Milenic DE; Overstreet T; Birch N; Le T; Brady ED; Brechbiel MW
J Med Chem; 2006 Mar; 49(6):2055-62. PubMed ID: 16539394
[TBL] [Abstract][Full Text] [Related]
8. Renal functional contrast-enhanced magnetic resonance imaging: evaluation of a new rapid-clearance blood pool agent (p792) in sprague-dawley rats.
Mandry D; Pedersen M; Odille F; Robert P; Corot C; Felblinger J; Grenier N; Claudon M
Invest Radiol; 2005 May; 40(5):295-305. PubMed ID: 15829826
[TBL] [Abstract][Full Text] [Related]
9. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
[TBL] [Abstract][Full Text] [Related]
10. Gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugate of arabinogalactan as a potential liver-targeting magnetic resonance imaging contrast agent.
Xiao Y; Xue R; You T; Li X; Pei F; Wang X; Lei H
Carbohydr Res; 2014 Aug; 395():9-14. PubMed ID: 24995911
[TBL] [Abstract][Full Text] [Related]
11. A new gadolinium-based contrast agent for magnetic resonance imaging of brain tumors: kinetic study on a C6 rat glioma model.
Fonchy E; Lahrech H; François-Joubert A; Dupeyre R; Benderbous S; Corot C; Farion R; Rubin C; Décorps M; Rémy C
J Magn Reson Imaging; 2001 Aug; 14(2):97-105. PubMed ID: 11477666
[TBL] [Abstract][Full Text] [Related]
12. Preparation and performance of biocompatible gadolinium polymer as liver-targeting magnetic resonance imaging contrast agent.
Hu T; Wan C; Zhan Y; Li X; Zheng Y
J Biosci Bioeng; 2024 Feb; 137(2):134-140. PubMed ID: 38195341
[TBL] [Abstract][Full Text] [Related]
13. Dynamic micro-magnetic resonance imaging of liver micrometastasis in mice with a novel liver macromolecular magnetic resonance contrast agent DAB-Am64-(1B4M-Gd)(64).
Kobayashi H; Saga T; Kawamoto S; Sato N; Hiraga A; Ishimori T; Konishi J; Togashi K; Brechbiel MW
Cancer Res; 2001 Jul; 61(13):4966-70. PubMed ID: 11431325
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and biodistribution study of self-assembled Gd-micelles demonstrating blood-pool contrast enhancement for MRI.
Vorobiev V; Babič A; Crowe LA; Van De Looij Y; Lenglet S; Thomas A; Helm L; Vallée JP; Allémann E
Int J Pharm; 2019 Sep; 568():118496. PubMed ID: 31279053
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of a new bioactivated paramagnetic gadolinium(III) complex [Gd(DOTA-FPG)(H2O)] for tracing gene expression.
Chang YT; Cheng CM; Su YZ; Lee WT; Hsu JS; Liu GC; Cheng TL; Wang YM
Bioconjug Chem; 2007; 18(6):1716-27. PubMed ID: 17935289
[TBL] [Abstract][Full Text] [Related]
16. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of [Gd(Bz-TTDA)]2- as a potential contrast agent in MR imaging of the hepatobiliary system: an animal study.
Hsu JS; Jaw TS; Liu GC; Wang YM; Chen SH; Kuo YT; Jao JC; Li CW; Tsai KB
J Magn Reson Imaging; 2004 Oct; 20(4):632-9. PubMed ID: 15390149
[TBL] [Abstract][Full Text] [Related]
18. Gd-complexes of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-1,4,7,10-tetraacetic acid (DOTA) conjugates of tranexamates as a new class of blood-pool magnetic resonance imaging contrast agents.
Gu S; Kim HK; Lee GH; Kang BS; Chang Y; Kim TJ
J Med Chem; 2011 Jan; 54(1):143-52. PubMed ID: 21141934
[TBL] [Abstract][Full Text] [Related]
19. Improved tumor-targeting MRI contrast agents: Gd(DOTA) conjugates of a cycloalkane-based RGD peptide.
Park JA; Lee YJ; Ko IO; Kim TJ; Chang Y; Lim SM; Kim KM; Kim JY
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):246-50. PubMed ID: 25449282
[TBL] [Abstract][Full Text] [Related]
20. Gadolinium chelate with DO3A conjugated 2-(diphenylphosphoryl)-ethyldiphenylphosphonium cation as potential tumor-selective MRI contrast agent.
Chandrasekharan P; Yong CX; Poh Z; He T; He Z; Liu S; Robins EG; Chuang KH; Yang CT
Biomaterials; 2012 Dec; 33(36):9225-31. PubMed ID: 23026708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
